Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 11X-Rays 8Biopsy 8Temozolomide 7Phantoms, Imaging 7Radiotherapy 6Nuclear Medicine Department, Hospital 6Bevacizumab 6erdafitinib 4Surgical Procedures, Operative 4Radiation 4Nivolumab 4Carmustine 4Carboplatin 4ulixertinib 3temsirolimus 3palbociclib 3olaparib 3larotrectinib 3Vorinostat 3Sunitinib 3IL13-PE38 3Chemotherapy, Adjuvant 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioma × Quality of Life × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡